Home » GlaxoSmithKline's Tyverb Gets Positive EMEA Opinion
GlaxoSmithKline's Tyverb Gets Positive EMEA Opinion
GlaxoSmithKline said it has received a positive opinion and conditional approval from the European Medicines Agency (EMEA) for its Tyverb cancer medicine after the product passed a Phase III trial.
Hemscott
Hemscott
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May